What is the ideal time to begin tapering opioid agonist treatment? A protocol for a retrospective population-based comparative effectiveness study in British Columbia, Canada
| Autor: | M Eugenia Socías, Evan Wood, Paul Gustafson, Robert W Platt, Bohdan Nosyk, Sander Greenland, Jeong Eun Min, Hui Xie, Shaun Seaman, P Todd Korthuis, Paxton Bach, B Carolina Guerra-Alejos, Megan Kurz, Tom Loughin, Ruyu Yan, Ehsan Karim, Lawrence McCandless, Kevin Schnepel |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | BMJ Open, Vol 14, Iss 4 (2024) |
| Druh dokumentu: | article |
| ISSN: | 2023-0834 2044-6055 |
| DOI: | 10.1136/bmjopen-2023-083453 |
| Popis: | Introduction Opioid agonist treatment (OAT) tapering involves a gradual reduction in daily medication dose to ultimately reach a state of opioid abstinence. Due to the high risk of relapse and overdose after tapering, this practice is not recommended by clinical guidelines, however, clients may still request to taper off medication. The ideal time to initiate an OAT taper is not known. However, ethically, taper plans should acknowledge clients’ preferences and autonomy but apply principles of shared informed decision-making regarding safety and efficacy. Linked population-level data capturing real-world tapering practices provide a valuable opportunity to improve existing evidence on when to contemplate starting an OAT taper. Our objective is to determine the comparative effectiveness of alternative times from OAT initiation at which a taper can be initiated, with a primary outcome of taper completion, as observed in clinical practice in British Columbia (BC), Canada.Methods and analysis We propose a population-level retrospective observational study with a linkage of eight provincial health administrative databases in BC, Canada (01 January 2010 to 17 March 2020). Our primary outcomes include taper completion and all-cause mortality during treatment. We propose a ‘per-protocol’ target trial to compare different durations to taper initiation on the likelihood of taper completion. A range of sensitivity analyses will be used to assess the heterogeneity and robustness of the results including assessment of effectiveness and safety.Ethics and dissemination The protocol, cohort creation and analysis plan have been classified and approved as a quality improvement initiative by Providence Health Care Research Ethics Board and the Simon Fraser University Office of Research Ethics. Results will be disseminated to local advocacy groups and decision-makers, national and international clinical guideline developers, presented at international conferences and published in peer-reviewed journals electronically and in print. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|